BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC

On March 15, 2024, BiomX Inc. has completed the offering. The transaction includes investor participation of certain institutional accredited investors, Deerfield Management Company and the AMR Action Fund, Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital. The transaction is subject to the approval of stockholder of the company.

OrbiMed Israel, as the general partner of OrbiMed BioFund, may be considered to hold indirectly 4,517,589 Shares, 4,327 shares of Series X Preferred Stock, 2,538,500 Warrants, and 9,280,408 Pre-Funded Warrants.